MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14760584.2026.2708184

Медицинская библиотека · Expert review of vaccines · 2026

Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study.

Blake Alexandre, Humphreys James, Olson Kate, Braeye Toon, Van Evercooren Izaak, Hansen Christian Holm, Moustsen-Helms Ida Rask, Fabiani Massimo, Mateo-Urdiales Alberto, Castilla Jesús, Martínez-Baz Iván, Machado Ausenda, Brito Andre, Ljung Rickard, Pihlström Nicklas, Mansiaux Yohann, Nicolay Nathalie, Monge Susana, Nunes Baltazar, VEBIS-EHR working group

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

We estimated the XBB.1.5 vaccine effectiveness (VE) against COVID-19 hospitalization and death in Belgium, Denmark, Italy, Portugal, Spain (Navarre), and Sweden following the 2023-24 fall vaccination campaign among immunocompromised persons (ICPs).

RESEARCH DESIGN AND

METHODS

We conducted a multi-country retrospective cohort study using electronic health records. Study sites identified ICPs aged ≥18 years through a common set of immunocompromising conditions and follow-up started the first day of the 2023 vaccination campaign until 12 months later. VE was calculated by time since vaccination (14-59, 60-119, 120-179, 180-365 days after vaccination) for ICPs by pooling study site level confounder adjusted hazard ratios (aHR) of vaccination, estimated with Cox proportional hazards regression models, using a random effect meta-analysis with VE = 100 × (1-pooled aHR).

RESULTS

The XBB.1.5 VE was 52% (95% confidence interval (CI): 41 to 60) and 75% (95%CI: 60 to 84) against hospitalization and death, respectively, 14-59 days after vaccination, and VE decreased with time since vaccination with no remaining protection at 180-365 days after vaccination.

CONCLUSION

Adapted XBB.1.5 vaccine provided moderate protection within 120 days after vaccination against severe COVID-19 outcomes among ICPs aged ≥18 years during a period with BA.2.86/JN.1 replacing the XBB.1.5 variant.

Для цитирования: Blake Alexandre, Humphreys James, Olson Kate, Braeye Toon, Van Evercooren Izaak, Hansen Christian Holm, Moustsen-Helms Ida Rask, Fabiani Massimo, Mateo-Urdiales Alberto, Castilla Jesús, Martínez-Baz Iván, Machado Ausenda, Brito Andre, Ljung Rickard, Pihlström Nicklas, Mansiaux Yohann, Nicolay Nathalie, Monge Susana, Nunes Baltazar, VEBIS-EHR working group. Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023-24 in six European countries: a VEBIS-EHR network study.. Expert review of vaccines. 2026. DOI: 10.1080/14760584.2026.2708184.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.